Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 06 - 22 symbols : NVO save search
Dicerna Initiates Patient Dosing in ESTRELLA Phase 2 Clinical Trial of Belcesiran for the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Published: 2021-06-22 (Crawled : 12:15) - biospace.com/
NVO | $123.9 -0.49% -0.47% 2.8M
|
Health Technology
|
| O: -0.39%
H: 0.27%
C: -0.21%
LLY | $750.77 -0.12% -0.23% 1.8M
|
Health Technology
|
| O: -0.02%
H: 0.44%
C: -0.53%
ALNY | $147.7 -0.54% -0.49% 330K
|
Health Technology
|
| O: 0.08%
H: 1.01%
C: 0.9%
disease liver disease treatment phase 2 liver trial
Innate Pharma Presents Preliminary Data from TELLOMAK Trial Showing Clinical Response for Lacutamab in Mycosis Fungoides
Published: 2021-06-22 (Crawled : 12:00) - biospace.com/
NVO | $123.9 -0.49% -0.47% 2.8M
|
Health Technology
|
| O: -0.39%
H: 0.27%
C: -0.21%
SNY | $46.24 0.68% 0.63% 1.6M
|
Health Technology
|
| O: -0.57%
H: 0.25%
C: -0.04%
IPHA | $2.42 -2.42% 3.88% 7.5K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -5.92%
trial response pharma
Gainers vs Losers
| 45% | 55% |
Top 10 Gainers
DYNT | $0.3704 -5.27% 43.09% 5.5M
|
Health Technology
BRTX | $1.32 -1.49% 20.71% 3.3M
|
Professional, Scientific, and T...
PTN | $1.82 -5.21% 15.38% 290K
|
Health Technology
VIAO | $0.308 -26.67% 12.01% 390K
|
Electronic Technology
HNRA | $2.36 -9.58% 11.86% 220K
|
n/a
HYLN 4 | $1.32 -7.04% 8.33% 800K
|
Producer Manufacturing
UMAC | $1.85 -2.12% 8.11% 6.1K
|
BQ | $0.2429 -6.07% 6.63% 99K
|
Consumer Non-Durables
GORO F | $0.534 -0.6% 6.55% 630K
|
Non-Energy Minerals
LBRT 4 | $22.1 -1.6% 6.29% 2.1M
|
Industrial Services
Your saved searches
Save your searches and get alerts when important news are released.